Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa
Glenda Gray, Ying Huang, Nicole Grunenberg, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 510
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Barton F. Haynes, Kevin Wiehe, Persephone Borrow, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 142-158
Open Access | Times Cited: 206
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
Glenda Gray, Linda‐Gail Bekker, Fatima Laher, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 12, pp. 1089-1100
Open Access | Times Cited: 185
Prevention, treatment and cure of HIV infection
Raphael J. Landovitz, Hyman Scott, Steven G. Deeks
Nature Reviews Microbiology (2023) Vol. 21, Iss. 10, pp. 657-670
Closed Access | Times Cited: 69
Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells
Mathieu Dubé, Olivier Tastet, Caroline Dufour, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 9, pp. 1507-1522.e5
Open Access | Times Cited: 43
Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions
Tiza L Nguni, Caroline Chasara, Zaza M. Ndhlovu
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 121
Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response
Davis W. Crews, Jenna A. Dombroski, Michael R. King
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 46
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zoe Moodie, One Dintwe, Sheetal Sawant, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 2, pp. 246-257
Open Access | Times Cited: 30
Cytokine response against vaccinia virus
S. Syed Shafi, Hafizurrahman Khan, Preeti Bajpai
Elsevier eBooks (2025), pp. 53-78
Closed Access
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity
Parker J. Jamieson, Xiaoying Shen, Alexandra A. Abu-Shmais, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses
Xiaoying Shen, Bette Korber, Rachel L. Spreng, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 133-133
Open Access
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview
Alex Boomgarden, Chitra Upadhyay
Vaccines (2025) Vol. 13, Iss. 2, pp. 148-148
Open Access
Tetraspanins: Host Factors in Viral Infections
ChihSheng New, Zhao-Yong Lee, Kai Sen Tan, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11609-11609
Open Access | Times Cited: 39
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects
Amitinder Kaur, Monica Vaccari
Viruses (2024) Vol. 16, Iss. 3, pp. 368-368
Open Access | Times Cited: 4
Vaccinia virus-based vector against infectious diseases and tumors
Ziling Zhang, Lanlan Dong, Chen Zhao, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 6, pp. 1578-1585
Open Access | Times Cited: 30
The Question of HIV Vaccine: Why Is a Solution Not Yet Available?
Martina Libera, Valeria Caputo, Giulia Laterza, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-20
Open Access | Times Cited: 3
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
Erica Andersen‐Nissen, Andrew Fioré-Gartland, Lamar Ballweber-Fleming, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 3, pp. e1009363-e1009363
Open Access | Times Cited: 25
Review of preventative HIV vaccine clinical trials in South Africa
Fatima Laher, Linda‐Gail Bekker, Nigel Garrett, et al.
Archives of Virology (2020) Vol. 165, Iss. 11, pp. 2439-2452
Open Access | Times Cited: 25
The search for an HIV vaccine, the journey continues
Carl W. Dieffenbach, Anthony S. Fauci
Journal of the International AIDS Society (2020) Vol. 23, Iss. 5
Open Access | Times Cited: 22
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
Xiaoying Shen, Fatima Laher, Zoe Moodie, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses
Per Johan Klasse, John P. Moore
Journal of Virology (2022) Vol. 96, Iss. 8
Open Access | Times Cited: 11
A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials
Susan Zolla‐Pazner, Nelson L. Michael, Jérôme H. Kim
The Lancet HIV (2021) Vol. 8, Iss. 7, pp. e449-e452
Open Access | Times Cited: 15
Recent insights into Fc-mediated effector responses to HIV-1
Margaret C. Carpenter, Margaret E. Ackerman
Current Opinion in HIV and AIDS (2020) Vol. 15, Iss. 5, pp. 282-289
Open Access | Times Cited: 14
Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines
Svenja Weiß, Vincenza Itri, Ruimin Pan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques
Archana V. Boopathy, Anurag Nekkalapudi, Janette Sung, et al.
Journal of Virology (2024) Vol. 98, Iss. 7
Open Access | Times Cited: 1
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
Lindsay Wieczorek, David Chang, Eric Sanders‐Buell, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top